Dr. Jörg Schickert

Dr. Jörg Schickert


Email joerg.schickert@​hoganlovells.com

Phone +49 89 290 12 198

Fax +49 89 290 12 222

LanguagesEnglish, French, German

Practice groupCorporate

"The team at Hogan Lovells, led by practice head Jörg Schickert is extremely broad and advises on all aspects of healthcare law. Jörg Schickert himself has extensive experienced in regulatory law and reimbursements."

Legal 500 Germany, 2018

If you work in the pharma, medical devices or biotech sector, it is Jörg Schickert who will be solving all your most complicated regulatory, commercial and compliance issues – for both Germany and all of Europe. His long-standing experience in dealing with German and European pharmaceutical and devices law means that he can circumspectly navigate you through all your reimbursement or pricing and reimbursement challenges. He will also aid you in drafting commercial/licensing contracts. Furthermore, you may turn to him with any most delicate criminal and compliance cases which your company might face. Jörg is very practical and always offers business-oriented solutions. He takes his industry knowledge from 15 years' experience in working hand-in-hand with many major and reputed life sciences companies.

Jörg is one of the few go-to lawyers in Europe for complex issues in the core business of the life sciences industry. He has a deep knowledge across all relevant legal areas of the day-to-day business of selling pharmaceutical products and devices or offering health solutions. This allows him to provide overall solutions for issues and projects which have implications in very different legal disciplines, such as regulatory, reimbursement, commercial, and compliance. He advises on reimbursement strategies, clinical trials, the launch and marketing of new products, dealing with health care professionals, anti-corruption/transparency, product safety and vigilance and related agreements and contracts. He also assists our corporate teams in transactions pertaining to the life science industry.Most recently, his life sciences industry team was named the Best Lawyers™ "Law firm of the year for pharmaceutical law" in Germany for the 2018 edition. The team is ranked in band 1 by JUVE, Chambers Global/Europe and LMG Germany, in 2017 as well as in preceding years.

Awards and recognitions


Acritas Star
Acritas Stars Independently Rated Lawyers


Recommended lawyer for pharmaceutical and medical device law
JUVE handbook


Industry Focus: Healthcare and Life Sciences, Leading Individual
Legal 500 EMEA


Leading lawyer for healthcare
Legal 500 Germany


Included for Health Care, Regulatory Practice and Pharmaceuticals law
Edition Best Lawyers™ in Germany, 2018


Life Sciences Europe Star for Regulatory and for Finance & Transactional
LMG Life Sciences

Education and admissions


Second State Exam in Law, Higher Regional Court of Nuremberg, 2001

Dr. iur., Friedrich-Alexander University Erlangen-Nürnberg, 2000

First State Exam in Law, Friedrich-Alexander University Erlangen-Nürnberg, 1996

Representative experience

Advising a leading pharmaceutical company on its innovative approach re digital health solutions alongside its pharma product offering in 21 countries on 4 continents.

Advising a U.S. medical devices company on regulatory and commercial issues regarding the market launch of a gene test in 24 European countries.

Advising Baxter regarding the regulatory and commercial law aspects of the sale and transfer of its renal replacement business to Nikkiso in 29 countries.

Advising a U.S. biotech client in the market launch in Europe (setting-up of EU distribution network, early access program, templates for compliance related agreements).

Advising a pharmaceutical and medical device company on a compliance investigation and its compliance structure in several EU countries.

Advising MorphoSys AG in drafting and negotiating a worldwide licence and collaboration agreement with Emergent Biosolutions re the joint development of an antibody.

Advising a leading U.S. biotech company on the HTA assessment before the German Federal Joint Committee (G-BA) and its strategy during price negotiations.

Loading data